ASCOconnection.org is a forum for the exchange of views on topical issues in the field of oncology. The views expressed in the blogs, comments, and forums belong to the authors. They do not necessarily reflect the views or positions of the American Society of Clinical Oncology. Please read the Commenting Guidelines.
At a time when every physician is needed, U.S. visa restrictions on international medical graduates are making it impossible for them to do the most good, writes Dr. Sreekanth Donepudi.
Jennifer Merschdorf of Young Survival Coalition and I discuss how she brings her business experience to the social-profit space and the value of partnerships in advocacy.
Dr. Jason Westin explains the science behind the transformative CAR T-cell therapy, and the financial concern it presents to our health care system and our patients.
ASCO's chief medical officer Dr. Richard L. Schilsky and I discuss the refinement of cancer surgery, the critical importance of federally funded research, and ASCO's research priorities for the oncology community.
"Quality improvement happens slowly if you're in a silo": Dr. Jeffery Ward and I discuss the important updates to ASCO's alternative payment model for high-quality oncology care.
As we begin our work in 2020, I am excited that we are building on the remarkable successes of 2019, and the years before, with growing collaboration and sharpening focus.
ASCO's delegation to the AMA HOD invites all ASCO members to share their thoughts and concerns concerning issues affecting the practice of oncology, as your input directly impacts the delegation's work.
As physicians, we have a responsibility to our patients in the clinic and in the ballot box. Ms. Talya Laufer and I advocate for a politically engaged and informed medical workforce.
Key cancer-related topics discussed at the AMA-HOD meeting included alcohol ingestion as a causation risk factor, appropriate guidelines for opioids in the cancer setting, and the use of de-identified patient information.
Health Equity Committee chair Dr. William D. Tap highlights the recent work and forward momentum of ASCO's efforts to achieve health care equity for all through improved access to and quality of care.
Dr. Ward and I discuss the policies that public and private insurers use to control the use of anticancer drug therapies, such as prior authorization requirements, restrictive formularies, step therapy, or fail first requirements, and specialty specific tiers.
Dr. Gottlieb discusses the FDA's efforts to increase overall efficiency by updating or modernizing aspects of our clinical trials conduct and expediting the end-to-end drug development process, as well as controlling the next generation of tobacco products.
Editor’s note: Dr. Hudis hosts the ASCO in Action Podcast, which focuses on policy and practice issues affecting providers and patients. An excerpt of a recent episode is shared below; it has been edited for length and clarity.
Dr. Elizabeth M. Blanchard outlines hot-button health policy issues that are likely to be legislative priorities in U.S. states during 2019-2020. Your voice can make an impact on these issues at the state level.
Blogs
ASCOconnection.org is a forum for the exchange of views on topical issues in the field of oncology. The views expressed in the blogs, comments, and forums belong to the authors. They do not necessarily reflect the views or positions of the American Society of Clinical Oncology. Please read the Commenting Guidelines.
No Results.
Pages
Advertisement